A comparison of the neurological toxicities of cisplatin-paclitaxel (PT) and cisplatin-cyclophosphamide (PC)

Bacon, Monica; Zee, Benny; James, Keith; Stuart, Gavin; Soroka, Dominique N.; Walsh, W. Bruce; Bacon, Eliza R.

doi:10.1016/s0959-8049(99)80535-8

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In an earlier report (preliminary analysis) of this work ( 14 ) , additional differences were found between the two treatment arms, that is, during treatment, a higher incidence in the PT arm of insomnia both as a toxicity and by patient assessment; worse patient‐assessed motor impairment in the PT arm during treatment; and, in the post treatment period, an increased duration of sensory toxicity in the PT arm. Also duration differences in ≥grade 3 sensory and motor toxicity during treatment and ≥grade 3 hearing toxicity in the follow‐up period were also reported in error.…”

Section: Resultsmentioning

confidence: 57%

A comparison of the incidence, duration, and degree of the neurologic toxicities of cisplatin-paclitaxel (PT) and cisplatin-cyclophosphamide (PC)

Bacon¹,

James²,

Zee³

2003

Int J Gynecol Cancer

Self Cite

View full text Add to dashboard Cite

Logically, the choice of any ultimate optimum therapy requires, as well as comparison of the survival outcomes, a comparison of both subjective and objective toxicities in terms of incidence, degree of severity, and duration. Frequently such detail is not collected in large studies. Both cisplatin and paclitaxel are effective but neurotoxic drugs for ovarian cancer. The optimum choice is further complicated in that carboplatin is a possible alternative for cisplatin, being less neurotoxic but having greater hematologic toxicity. Similarly, 3-h and 24-h infusion schedules of paclitaxel have different incidences in opposite directions of hematologic and neurologic toxicities. One hundred fifty two eligible Canadian patients entered in a European-Canadian study that compared paclitaxel-cisplatin (PT, 79) patients with cyclophosphamide-cisplatin (PC, 73 patients) had both subjective and objective neurotoxicity data collected from treatment initiation to disease progression. Incidence, degree, and duration (compared in an analogous way to remission durations) of neurotoxicity were compared in the two arms to quantify the additional paclitaxel toxicity. No significant differences were found for motor toxicity, motor impairment, hearing impairment, or insomnia. For sensory changes during treatment, toxicity (all grades, 91% vs. 49%; grade 3 or higher, 29% vs. 3%) incidence, subjective impairment (a little or more, 89% vs. 40%; lots, 54% vs. 11%) incidence, and toxicity duration (all grades only), and impairment durations (both degrees) were all worse for PT. During follow-up, only the incidence of all-grade sensory toxicity was worse and this was not reflected by any other parameters. We conclude that paclitaxel adds considerably, but only temporarily, to the sensoy neurotoxicity of cisplatin.

show abstract

Section: Resultsmentioning

confidence: 57%

A comparison of the incidence, duration, and degree of the neurologic toxicities of cisplatin-paclitaxel (PT) and cisplatin-cyclophosphamide (PC)

Bacon¹,

James²,

Zee³

2003

Int J Gynecol Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…In an earlier report (preliminary analysis) of this work (14) , additional differences were found between the two treatment arms, that is, during treatment, a higher incidence in the PT arm of insomnia both as a toxicity and by patient assessment; worse patientassessed motor impairment in the PT arm during treatment; and, in the post treatment period, an increased duration of sensory toxicity in the PT arm. Also duration differences in grade 3 sensory and motor toxicity during treatment and grade 3 hearing toxicity in the follow-up period were also reported in error.…”

Section: Notementioning

confidence: 52%

A comparison of the incidence, duration, and degree of the neurologic toxicities of cisplatin-paclitaxel (PT) and cisplatin-cyclophosphamide (PC)

Bacon

James

Zee

2003

Int J Gynecol Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

A comparison of the neurological toxicities of cisplatin-paclitaxel (PT) and cisplatin-cyclophosphamide (PC)

Cited by 2 publications

References 0 publications

A comparison of the incidence, duration, and degree of the neurologic toxicities of cisplatin-paclitaxel (PT) and cisplatin-cyclophosphamide (PC)

A comparison of the incidence, duration, and degree of the neurologic toxicities of cisplatin-paclitaxel (PT) and cisplatin-cyclophosphamide (PC)

A comparison of the incidence, duration, and degree of the neurologic toxicities of cisplatin-paclitaxel (PT) and cisplatin-cyclophosphamide (PC)

Contact Info

Product

Resources

About